# An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

> **NCT01013610** · PHASE1 · COMPLETED · sponsor: **Link Medicine Corporation** · enrollment: 110 (estimated)

## Conditions studied

- Mild Alzheimer's Disease

## Interventions

- **DRUG:** LNK-754
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01013610
- **Lead sponsor:** Link Medicine Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2011-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013610, "An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01013610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*